Cost–Effectiveness of Rivaroxaban Compared to Warfarin for Stroke Prevention in Atrial Fibrillation
Authors:
- Moise W. AngladeMAMoise W. Anglade
- Dan PhamDPDan Pham
- Robyn PisacaneRPRobyn Pisacane
- Jeffrey KlugerJKJeffrey Kluger
- Craig I. ColemanCCCraig I. Coleman
- 1 September 2012
- journal article
- research article
- Published by Elsevier in The American Journal of Cardiology
- Vol. 110 (6) , 845-851
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- Cost-Effectiveness of Dabigatran Compared With Warfarin for Stroke Prevention in Patients With Atrial Fibrillation and Prior Stroke or Transient Ischemic AttackStroke, 2012
- 2011 ACCF/AHA/HRS Focused Update on the Management of Patients With Atrial Fibrillation (Update on Dabigatran)JACC, 2011
- Cost-effectiveness of dabigatran etexilate for the prevention of stroke and systemic embolism in atrial fibrillation: A Canadian payer perspectiveThrombosis and Haemostasis, 2011
- Patient characteristics associated with oral anticoagulation control: results of the Veterans AffaiRs Study to Improve Anticoagulation (VARIA)Journal of Thrombosis and Haemostasis, 2010
- Treatments for stroke prevention in atrial fibrillation: A network meta-analysis and indirect comparisons versus dabigatran etexilateThrombosis and Haemostasis, 2010
- Patterns of Hospital Performance in Acute Myocardial Infarction and Heart Failure 30-Day Mortality and ReadmissionCirculation: Cardiovascular Quality and Outcomes, 2009
- Preference-Based EQ-5D Index Scores for Chronic Conditions in the United StatesMedical Decision Making, 2006
- Risk Factors for Intracerebral Hemorrhage in the General PopulationStroke, 2003
- Atrial fibrillation is associated with an increased risk for mortality and heart failure progression in patients with asymptomatic and symptomatic left ventricular systolic dysfunction: a retrospective analysis of the SOLVD trialsJACC, 1998
- Long-term survival after first-ever stroke: the Oxfordshire Community Stroke Project.Stroke, 1993